From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

tildrakizumab   Click here for help

GtoPdb Ligand ID: 8093

Synonyms: Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn
Approved drug Immunopharmacology Ligand
tildrakizumab is an approved drug (EMA & FDA (2018))
Compound class: Antibody
Comment: Tildrakizumab is a monoclonal antibody directed against the p19 subunit of IL-23 (IL-23A). It exhibits efficacy in treating psoriasis [1,4]. This biologic agent may be beneficial for patients who do not tolerate current antitumour necrosis factor (TNF) therapies.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-23A Primary target of this compound Hs Antibody Binding 9.5 – 9.5 pKd - 2,5
⤷ pKd 9.5 (Kd 2.86x10-10 M) [5]
pKd 9.5 (Kd 2.97x10-10 M) [2]
Description: Binding affinity constant for clone 13B8-b CDRH2-b.